Experimental therapy on Duchenne muscular dystrophy;Experimentele therapie bij duchenne-spierdystrofie

Nederlands Tijdschrift voor Geneeskunde

Volumn 153, Issue 18, 2009, Pages 870-875

  Van den Bergen, Janneke C ^a   Straathof, Chiara S M ^a   Aartsma Rus, Annemieke ^a   Ginjaar, Leke B ^a   Verschuuren, Jan J G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORTICOSTEROID;

DISEASE COURSE; DRUG DESIGN; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE THERAPY; HUMAN; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STOP CODON;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CODON, TERMINATOR; DISEASE PROGRESSION; DRUG DESIGN; EXONS; GENE THERAPY; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE;

EID: 67449094466     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 1 Den Dunnen JT, de Visser VM, Bakker E. Van gen naar ziekte; het dystrofinegen, betrokken bij Duchenne- en Becker-spierdystrofie. Ned Tijdschr Geneeskd. 2002;146:364-7.
2. Aartsma-Rus A, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34:135-44.
3. 3 Van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357:2677-86.
4. 4 Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 2002;i2(Suppl i):S7i-7.
5. Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet. 2007:8:43.
6. 6 Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al.PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87-91-
7. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375-81.
8. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 2001;49:706-11.
9. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47:430-44.
10. 10 Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA. 2008;105:2064-9.
11. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA. 2000;97:13714-9.
12. Deconinck N, Tinsley J, de Backer F, Fisher R, Kahn D, Phelps S, et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med. 1997;3:1216-21.
13. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4:1441-4.
14. Gissel H. The role of Ca2+ in muscle cell damage. Ann N Y Acad Sci. 2005;1066:166-80.
15. 15 Spencer MJ, Mellgren RL. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet. 2002;11:2645-55.
16. Badalamente MA, Stracher A. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle Nerve. 2000;23:106-11.
17. Hinkle RT, Lefever FR, Dolan ET, Reichart DL, Dietrich JA, Gropp KE, et al. Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Med. 2007:5:18.
18. Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70:137-43.
19. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204-10.
20. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve. 2006;34:327-34.
21. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561-71.
22. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle- specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137-48.
23. Shavlakadze T, White J, Hoh JF, Rosenthal N, Grounds MD. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Then 2004;10:829-43.
24. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006;12:1147-50.
25. Brunelli S, Sciorati C, DAntona G, Innocenzi A, Covarello D, Galvez BG, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA. 2007;104:264-9.
26. Liu Y, Yan X, Sun Z, Chen B, Han Q, Li J, et al. Flk-i(+) adipose-derived mesenchymal stem cells differentiate into skeletal muscle satellite cells and ameliorate muscular dystrophy in MDX mice. Stem Cells Dev. 2007;16:695-706.
27. Smpaolesi M, Blot S, DAntona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;444:574-9.
28. Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, Pisati F, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant. 2007;16:563-77.